Ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension by 55%, according to recent study results.
A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children, but ...
In a widely expected decision, the Food and Drug Administration approved Merck’s Winrevair for injection, making it the first activin signaling inhibitor therapy for pulmonary arterial hypertension ...
Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...
Please provide your email address to receive an email when new articles are posted on . The Kids MoD PAH Trial is recruiting pediatric patients with newly diagnosed PAH. Sildenafil plus bosentan vs.
Add Yahoo as a preferred source to see more of our stories on Google. At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, researchers shared pooled results from three ...
Early initiation of macitentan and tadalafil therapy in PAH patients results in similar survival and hospitalization rates, regardless of diagnosis timing. Newly diagnosed PAH patients often present ...
Pulmonary arterial hypertension (PAH) is a condition where you have high blood pressure in the arteries that go from your heart to your lungs. In people with PAH, the arteries become narrow, stiff, or ...
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...
The ZENITH trial demonstrated sotatercept's efficacy in reducing severe outcomes in high-risk PAH, leading to early trial termination for efficacy. Oral semaglutide in the SOUL trial reduced major ...
Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 24. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the ...